Summit Therapeutics (SMMT) Net Equity Issued and Repurchased (2019 - 2025)

Summit Therapeutics (SMMT) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $468.3 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 11706925.0% year-over-year to $468.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $543.1 million (up 1161.98% YoY) and the FY2025 annual result came in at $500.0 million, up 1061.98% from the prior year.
• Net Equity Issued and Repurchased climbed to $468.3 million in Q4 2025, from $31.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $468.3 million in Q4 2025 to a low of -$619000.0 in Q3 2023.
• A 4-year average of $93.5 million and a median of $37.4 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased sank 100.65% — and 2025, when it jumped 11706925.0%.
• Tracing SMMT's Net Equity Issued and Repurchased over 4 years: stood at $100.0 million in 2022, then plunged by 99.38% to $619000.0 in 2023, then tumbled by 100.65% to -$4000.0 in 2024, then jumped by 11706925.0% to $468.3 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $468.3 million (Q4 2025), $31.8 million (Q3 2025), and -$4000.0 (Q4 2024), per Business Quant data.